In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Fampridine, a drug used to improve walking in people with multiple sclerosis, may also improve working memory in certain healthy individuals. The findings pave the way for potential new treatments for ...

Quantum BioPharma Ltd. has announced an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application package for Lucid-21-302 ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Widespread formulary exclusions Numerous medicines have been approved in recent years to help patients manage symptoms of MS, a potentially debilitating disease that attacks the central nervous system ...